Clovis Oncology Inc logo

CLVS

Clovis Oncology Inc

$1.34

Earnings Summary

Revenue
$34.25Mn
Net Profits
$-60.17Mn
Net Profit Margins
-175.69%

Highlights

Revenue:

Clovis Oncology Inc’s revenue fell -10% since last year same period to $34.25Mn in the Q1 2022. On a quarterly growth basis, Clovis Oncology Inc has generated -4.78% fall in its revenue since last 3-months.

Net Profits:

Clovis Oncology Inc’s net profit jumped 9.22% since last year same period to $-60.17Mn in the Q1 2022. On a quarterly growth basis, Clovis Oncology Inc has generated 6.56% jump in its net profits since last 3-months.

Net Profit Margins:

Clovis Oncology Inc’s net profit margin fell -0.87% since last year same period to -175.69% in the Q1 2022. On a quarterly growth basis, Clovis Oncology Inc has generated 1.86% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Clovis Oncology Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.41
EPS Estimate Current Year
-0.41

Highlights

EPS Estimate Current Quarter:

Clovis Oncology Inc’s earning per share (EPS) estimates for the current quarter stand at -0.41 - a 4.65% jump from last quarter’s estimates.

EPS Estimate Current Year:

Clovis Oncology Inc’s earning per share (EPS) estimates for the current year stand at -0.41.

Key Ratios

Key ratios of the Clovis Oncology Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.44
Return on Assets (ROA)
-0.28
Return on Equity (ROE)
0
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Clovis Oncology Inc’s earning per share (EPS) jumped 31.25% since last year same period to -0.44 in the Q1 2022. This indicates that the Clovis Oncology Inc has generated 31.25% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Clovis Oncology Inc’s return on assets (ROA) stands at -0.28.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Clovis Oncology Inc’s return on equity (ROE) stands at 0.

Dividend Per Share (DPS):

Clovis Oncology Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.43
-0.44
-2.33%

Company Information

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, with additional office locations in the U.S. and Europe.

Organisation
Clovis Oncology Inc
Headquarters
Boulder, Colorado, US
Employees
429
Industry
Health Technology
CEO
Patrick Mahaffy